Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Identification and characterization of the tumoral intermediaries on the overflowing peritoneal
Study Overview
Brief Summary
To confirm the role of the collective dissemination in the mechanisms of tumoral invasion of colorectal cancers
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age > 18 years
- •Histological Diagnosis of stage IV colorectal cancer
- •Hepatic metastasis and/or peritoneal potentially resecable
- •Patient affiliated with a mode of the social security or recipient of such a mode
- •Information of the patient or his legal representative and collection of his assent
Exclusion Criteria
- •None metastatic colorectal cancer
- •Cancer of appendicular origin
- •Patients deprived of liberty or unable to give his assent
Arms & Interventions
Patients with metastatic colorectal cancer
After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.
The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:
- Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal
- Peritoneal liquid
- none tumoral peritoneum
- Portal blood
- Peripheral blood
- Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.
In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator.
Intervention: Sampling (Procedure)
Outcomes
Primary Outcomes
Identification and characterization of the tumoral intermediaries on the overflowing peritoneal
Time Frame: Up to 24 months
After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45.
Identification and characterization of the tumoral intermediaries on the portal blood
Time Frame: Up to 24 months
After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45.
Identification and characterization of the tumoral intermediaries on the peripheral blood
Time Frame: Up to 24 months
After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45.
Identification and characterization of the tumoral intermediaries on the hepatic metastasis and/or peritoneal)
Time Frame: Up to 24 months
After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45.
Secondary Outcomes
No secondary outcomes reported